[ad_1]
The local pharmaceutical company expects to sell 80 million US dollars abroad this year, after sealing the deal.
Lina Maria Guevara Benavides
"This acquisition makes Tecnoquímicas the sole owner of the MK brand in Central America, the Caribbean and South America (except Venezuela)." This was confirmed by the Colombian company Tecnoquímicas (TQ), chaired by Francisco Barberi, at the conclusion of the negotiation with the German pharmaceutical company Bayer, which had until now the exploitation of the brand MK in 23 countries of Latin America
. about the purchase of Bonima SA of C.V., owner of these 23 companies; and the acquisition of a plant in El Salvador, which joins the 11 factories that the company already owns: eight in Colombia (one in Bogotá, five in Valle del Cauca and two in Cauca) and three in Salvador. 19659005] "Tecnoquímicas had only two countries operating with MK, now we have Panama, Costa Rica, Nicaragua, El Salvador, Honduras, Guatemala, the Dominican Republic and different markets in the Caribbean", explained Emilio Sardi, executive vice president of Tecnoquímica. He referred to the newly acquired plant in El Salvador. "This is a plant fully adapted to the good manufacturing practices that the MK line produces today and which is part of Bayer's portfolio," Sardi said.
According to the director, production will continue for now, but TQ will evaluate the possibility of transferring part of their local production because "on the local market, there is very little support for domestic production" .
The maker of brands such as Bonfiest, Frutas Lua's Sal, Altex, Winny, Crema No. 4, Noraver, Hidraplus and Yodora explained that "the operation will significantly boost the growth of the brand's participation MK in the markets where she is present ". In this sense, the pharmaceutical company plans to sell US $ 80 million abroad in 2018 and US $ 100 million in 2019, also outside Colombia.
In fact, according to the figures provided by the Superintendency of Enterprises closing fiscal year last year, Tecnoquímicas is the third largest pharmaceutical company with the highest turnover figure, after 1.4 trillion dollars in revenue ($ 508 million) and $ 152,010 million in profits, with an increase of 64.7% in The transaction between TQ and Bayer, whose value remains confidential (even though Sardi has ensured that MK is a brand that adds sales of 35 million US dollars to the world), is known only a day after The director of Boehringer Ingelheim in Colombia will explain the business strategy that he will have with the transaction that & # 39; 39, he carried out with Sanofi, in particular the sale of his portfolio of mass drug products (including the traditional brand Isodine) to Boehringer while selling a part of its business, it acquired the Sanofi's Animal Health Portfolio for $ 8,000 million. With this business sector, the company plans to concentrate 35% of this niche on the local market. The bet will be launched from this month in the country.
"For 10 years the pharmaceutical industry has made mergers and exchanges of portfolios, it is not something new, but in our case, this operation is related to the desire of TQ d & # 39; 39, apply our market knowledge to a larger region, "said Sardi.
[ad_2]
Source link
